Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenjiro Ono

Showing results (1-10 of 278) with videos related to

Pageof 28
Sort By:
Neurochemical Research|August 23, 2017
The Oligomer Hypothesis in α-SynucleinopathyKenjiro Ono
Neurochemistry International|August 20, 2017
Alzheimer's disease as oligomeropathyKenjiro Ono
Brain and Nerve = Shinkei Kenkyu No Shinpo|February 10, 2020
[α-Synuclein as Diagnostic Biomarker]Kenjiro Ono
Geriatrics & Gerontology International|January 7, 2012
Vitamin A and Alzheimer's diseaseKenjiro Ono, Masahito Yamada
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 7, 2024
[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]Moeko Shinohara, Kenjiro Ono
Journal of Neurochemistry|January 20, 2011
Low-n oligomers as therapeutic targets of Alzheimer's diseaseKenjiro Ono, Masahito Yamada
Neurobiology of Disease|December 16, 2006
Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseasesKenjiro Ono, Masahito Yamada
Journal of Multidisciplinary Healthcare|September 17, 2021
Takotsubo Syndrome: Optimizing Care with a Multidisciplinary ApproachRyuta Kinno, Kenjiro Ono
Journal of Neurochemistry|March 10, 2006
Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitroKenjiro Ono, Masahito Yamada
Frontiers in Pharmacology|June 14, 2019
Pharmacological Potential of Cilostazol for Alzheimer's DiseaseKenjiro Ono, Mayumi Tsuji
Pageof 28

Showing results (1-10 of 278) with videos related to

Sort By:
Pageof 28
Neurochemical Research|August 23, 2017
The Oligomer Hypothesis in α-SynucleinopathyKenjiro Ono
Neurochemistry International|August 20, 2017
Alzheimer's disease as oligomeropathyKenjiro Ono
Brain and Nerve = Shinkei Kenkyu No Shinpo|February 10, 2020
[α-Synuclein as Diagnostic Biomarker]Kenjiro Ono
Geriatrics & Gerontology International|January 7, 2012
Vitamin A and Alzheimer's diseaseKenjiro Ono, Masahito Yamada
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 7, 2024
[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]Moeko Shinohara, Kenjiro Ono
Journal of Neurochemistry|January 20, 2011
Low-n oligomers as therapeutic targets of Alzheimer's diseaseKenjiro Ono, Masahito Yamada
Neurobiology of Disease|December 16, 2006
Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseasesKenjiro Ono, Masahito Yamada
Journal of Multidisciplinary Healthcare|September 17, 2021
Takotsubo Syndrome: Optimizing Care with a Multidisciplinary ApproachRyuta Kinno, Kenjiro Ono
Journal of Neurochemistry|March 10, 2006
Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitroKenjiro Ono, Masahito Yamada
Frontiers in Pharmacology|June 14, 2019
Pharmacological Potential of Cilostazol for Alzheimer's DiseaseKenjiro Ono, Mayumi Tsuji
Pageof 28